

August 23, 1969

Dr. Allen Borger
Chas. Pfizer & Co.
Groton, Connecticut

Ref: CP 14-368

Dear Allen,

We have completed an initial set of trials of CP-14,368 in volunteers, in single oral dosages of 50 to 350 mg. The latter dose was in a single trial.

To date, we have failed to observe behavioral or EEG effects during the initial 2 hour observation period; and the subjects reported no behavioral consequences for the ensuing 12 to 20 hours.

To continue these trials, we wish to amend the protocol submitted earlier, to allow trials (single, oral) to 500 mg.

Please verify.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

mf/